Company profile: X-Body Biosciences
1.1 - Company Overview
Company description
- Provider of biotechnology R&D focused on discovering and developing compounds against therapeutic targets in oncology and ophthalmology, including discovery of human antibodies against high-value targets; engages in alliances with other corporations.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to X-Body Biosciences
Immunovant
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical offerings focused on enabling normal lives for patients with autoimmune diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunovant company profile →
Tiziana Life Sciences
HQ: United Kingdom
Website
- Description: Provider of biotechnology therapies focused on discovery and development of novel molecules in oncology and immunology, including Intranasal Foralumab (anti-CD3 nasal immunotherapy for neuroinflammatory and neurodegenerative diseases), Anti IL-6R mAb (TZLS-501) to reduce inflammation in idiopathic pulmonary fibrosis and autoimmune diseases, and Milciclib, a CDK-targeting cancer therapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tiziana Life Sciences company profile →
NexImmune
HQ: United States
Website
- Description: Provider of immuno-therapeutics using proprietary AIM artificial immune technology, including AIM ACT, a cellular therapy using AIM nanoparticles to orchestrate specific T cell functions for cancer treatment; AIM INJ, an injectable AIM nanoparticle product targeting disease-specific T cells; and Phase 1/2 candidates NEXI-001 (AML) and NEXI-002 (multiple myeloma).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NexImmune company profile →
Apexigen
HQ: United States
Website
- Description: Provider of clinical-stage immuno-oncology antibody therapeutics for cancer, including sotigalimab (PYX-107), a Phase 2 CD40 agonist with demonstrated anti-cancer activity in patients who have progressed on PD-(L)1 inhibitors, and the APXiMAB platform for generating novel antibodies optimized for targeted payload delivery in antibody-drug conjugates.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Apexigen company profile →
Cidara Therapeutics
HQ: United States
Website
- Description: Provider of drug-Fc conjugate therapeutics built on the Cloudbreak platform, which couples targeted small molecules and peptides to a human antibody fragment (Fc) to inhibit disease targets and engage the immune system; includes CD388, a Phase 2 DFC for preventing seasonal influenza A and B, and CBO421, an IND-enabling oncology DFC targeting CD73 to enhance anti-tumor immunity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cidara Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for X-Body Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to X-Body Biosciences
2.2 - Growth funds investing in similar companies to X-Body Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for X-Body Biosciences
4.2 - Public trading comparable groups for X-Body Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →